https://www.ncbi.nlm.nih.gov/pmc/articles/PMC96596
Post# of 148179
(Total Views: 499)
Posted On: 05/01/2024 6:16:28 AM
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659683/
Leronlimab in the treatment of Long COVID
Leronlimab is an IgG4 monoclonal antibody which belongs to the species of CCR5 antagonists. It acts by immunomodulation and regulating the immune reactions within the body, it has been successfully used to treat individuals with acute COVID-19. A study conducted by Gaylis et al, on Leronlimab in Long COVID believe that the pathogenesis of the syndrome may be linked with CCR5 and its abnormal downregulation. The study concluded that the immuno-down regulation was normalized in patients treated with Leronlimab and with further investigation in the current ongoing trials (NCT0434365, NCT04347239, NCT04678830) may prove to be a treatment for long COVID [16].
Leronlimab in the treatment of Long COVID
Leronlimab is an IgG4 monoclonal antibody which belongs to the species of CCR5 antagonists. It acts by immunomodulation and regulating the immune reactions within the body, it has been successfully used to treat individuals with acute COVID-19. A study conducted by Gaylis et al, on Leronlimab in Long COVID believe that the pathogenesis of the syndrome may be linked with CCR5 and its abnormal downregulation. The study concluded that the immuno-down regulation was normalized in patients treated with Leronlimab and with further investigation in the current ongoing trials (NCT0434365, NCT04347239, NCT04678830) may prove to be a treatment for long COVID [16].
(7)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼